Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)".
作者信息
Celio Luigi, Antonuzzo Andrea, Aapro Matti S
机构信息
Medical Oncology Unit 4, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland.
出版信息
Br J Cancer. 2024 Apr;130(6):895-896. doi: 10.1038/s41416-024-02611-z. Epub 2024 Feb 26.
Abstract
摘要
相似文献
1
Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)".关于“在顺铂治疗中，第2 - 4天联合使用帕洛诺司琼、神经激肽-1受体拮抗剂和奥氮平减少地塞米松用量：一项随机III期试验（SPARED试验）”的评论
Br J Cancer. 2024 Apr;130(6):895-896. doi: 10.1038/s41416-024-02611-z. Epub 2024 Feb 26.
2
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).地塞米松在第 2-4 天的节约作用与联合帕洛诺司琼、神经激肽-1 受体拮抗剂和奥氮平在顺铂治疗中的应用：一项随机 III 期试验（SPARED 试验）。
Br J Cancer. 2024 Feb;130(2):224-232. doi: 10.1038/s41416-023-02493-7. Epub 2023 Nov 16.
3
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.SPARED 试验方案：比较第 1 天给予地塞米松与第 1-4 天给予地塞米松，联合神经激肽-1 受体拮抗剂、帕洛诺司琼和奥氮平（5mg）在接受顺铂为基础化疗的患者中的随机非劣效性 III 期试验。
BMJ Open. 2020 Dec 17;10(12):e041737. doi: 10.1136/bmjopen-2020-041737.
4
Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India.奥氮平与NK1受体拮抗剂预防卡铂所致（曲线下面积≥4）呕吐的疗效比较：一项来自印度的III期双盲安慰剂对照随机试验
JCO Glob Oncol. 2025 Mar;11:e2400166. doi: 10.1200/GO.24.00166. Epub 2025 Mar 24.
5
Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.与其他药物相比，神经激肽-1受体拮抗剂帕洛诺司琼与地塞米松联合用于预防化疗引起的恶心和呕吐的疗效：一项随机对照试验的系统评价和荟萃分析
Ann Palliat Med. 2018 Apr;7(2):221-233. doi: 10.21037/apm.2018.03.09.
6
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.奥氮平三联疗法与神经激肽-1 受体拮抗剂三联疗法预防高致吐性化疗所致恶心呕吐的比较：一项网络荟萃分析。
Oncologist. 2018 May;23(5):603-616. doi: 10.1634/theoncologist.2017-0378. Epub 2018 Jan 12.
7
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.奥氮平用于预防和治疗成人癌症相关性恶心和呕吐。
Cochrane Database Syst Rev. 2018 Sep 21;9(9):CD012555. doi: 10.1002/14651858.CD012555.pub2.
8
Clinical benefits of adding olanzapine to 5-HT receptor antagonist, NK receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.在高致吐性化疗中，添加奥氮平至5-羟色胺受体拮抗剂、NK受体拮抗剂和地塞米松用于预防恶心和呕吐的临床益处：来自日本临床肿瘤学会《2023年止吐临床实践指南》的系统评价和荟萃分析
Int J Clin Oncol. 2025 Jan;30(1):27-39. doi: 10.1007/s10147-024-02663-4. Epub 2024 Nov 21.
9
Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.紫杉烷类作为晚期非小细胞肺癌的一线治疗：一项系统评价与实践指南
Lung Cancer. 2005 Dec;50(3):355-74. doi: 10.1016/j.lungcan.2005.06.010. Epub 2005 Aug 31.
10
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.奥氮平5毫克联合三联止吐药用于含蒽环类方案治疗乳腺癌患者的总体疗效和安全性：一项3期、双盲、随机、安慰剂对照试验。
Lancet Oncol. 2025 Jun 17. doi: 10.1016/S1470-2045(25)00233-5.
引用本文的文献
1
Multi-day vs single-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.多日与单日地塞米松预防化疗引起的恶心和呕吐的比较：系统评价和荟萃分析。
Support Care Cancer. 2024 Oct 21;32(11):736. doi: 10.1007/s00520-024-08934-0.
2
Reply to L. Celio et al.对L. 塞利奥等人的回复
Br J Cancer. 2024 Jun;130(12):1887-1888. doi: 10.1038/s41416-024-02708-5. Epub 2024 May 15.
本文引用的文献
1
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.2023 MASCC 和 ESMO 指南更新：预防化疗和放疗引起的恶心和呕吐。
ESMO Open. 2024 Feb;9(2):102195. doi: 10.1016/j.esmoop.2023.102195. Epub 2024 Jan 11.
2
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.2023 更新 MASCC/ESMO 共识建议：预防高致吐风险抗肿瘤药物所致恶心呕吐。
Support Care Cancer. 2023 Dec 21;32(1):47. doi: 10.1007/s00520-023-08221-4.
3
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).地塞米松在第 2-4 天的节约作用与联合帕洛诺司琼、神经激肽-1 受体拮抗剂和奥氮平在顺铂治疗中的应用：一项随机 III 期试验（SPARED 试验）。
Br J Cancer. 2024 Feb;130(2):224-232. doi: 10.1038/s41416-023-02493-7. Epub 2023 Nov 16.
4
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).探索性分析地塞米松节约方案预防顺铂诱导呕吐对食物摄入的影响（LUNG-NEPA 研究）。
Sci Rep. 2023 Jan 23;13(1):1257. doi: 10.1038/s41598-023-28464-9.
5
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.评价在顺铂治疗环境下接受 NETPA（奈妥匹坦/帕洛诺司琼）方案的地塞米松节省止吐方案中，化疗引起的恶心和呕吐对患者日常功能的影响：一项随机 3 期研究的结果。
BMC Cancer. 2022 Aug 24;22(1):915. doi: 10.1186/s12885-022-10018-3.
6
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.地塞米松节省方案联合口服奈妥吡坦和帕洛诺司琼预防高剂量顺铂所致呕吐：一项随机非劣效性研究。
Oncologist. 2021 Oct;26(10):e1854-e1861. doi: 10.1002/onco.13851. Epub 2021 Jun 18.
7
Antiemetics: ASCO Guideline Update.止吐药：ASCO 指南更新。
J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13.
8
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.奥氮平 5 毫克联合标准止吐疗法预防化疗引起的恶心和呕吐（J-FORCE）：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2020 Feb;21(2):242-249. doi: 10.1016/S1470-2045(19)30678-3. Epub 2019 Dec 11.
Zotero 插件